Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial
합성 다항원 변형 백시니아 바이러스 앙카라 기반 COVID-19 백신(COH04S1)의 안전성 및 면역원성: 공개 및 무작위 배정, 1상 시험
Clinical Trial
[키워드] 95% CI
Administered
Adults
Analysis
Anxiety
assigned
baseline
body-mass
body-mass index
boost
Cellular responses
center
city
Cohort
Comprehensive
Concentration
COVID-19 vaccine
development
dose
drug
eight
fatigue
female
Fever
Fisher
Fisher's exact test
FIVE
followed by
foundation
Future
GRADE
grade 3
Haematology
healthy
High dose
High-dose
Hope
IgG
immunogenicity
immunological
increase in
initiated
injection
interferon
interferon-γ
Intramuscular injection
less
limit
low dose
low-dose
medium dose
modified vaccinia virus
modified vaccinia virus Ankara
Moss
negative pregnancy test
nine
nucleocapsid
nucleocapsid antigens
nucleocapsid protein
nucleocapsid-specific antibody
Open-label
outcome
participant
PCR test
Phase 1
phase 1 trial
Placebo
placebo group
plaque-forming unit
plaque-forming units
poxvirus
pregnancy test
Primary outcome
provided
randomised
Randomly
receive
Registered
reported
risk
Safety
SARS-CoV-2 antibody
SARS-CoV-2 neutralising antibodies
SARS-CoV-2 neutralising antibody
SARS-CoV-2 spike
Secondary objectives
secondary outcome
secreting
Seroconversion
seroconversion rate
seroconversion rates
Seven
severe adverse event
severe adverse events
Spike protein
statistical
T cell
T cells
T-cell responses
titre
Tolerability
Trial
troponin
USA
vaccination
Vaccine
Viral
viral neutralisation
was done
was measured
was tested
[DOI] 10.1016/S2666-5247(22)00027-1 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1016/S2666-5247(22)00027-1 PMC 바로가기 [Article Type] Clinical Trial